Euroasian journal of hepato-gastroenterology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  13 (2023)
Volume  12 (2022)
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Volume  1 (2011)
Related articles

VOLUME 7 , ISSUE 1 ( January-June, 2017 ) > List of Articles

MINI REVIEW

Managing Encephalopathy in the Outpatient Setting

Tarana Gupta, Sahaj Rathi, Radha K Dhiman

Citation Information : Gupta T, Rathi S, Dhiman RK. Managing Encephalopathy in the Outpatient Setting. Euroasian J Hepatogastroenterol 2017; 7 (1):48-54.

DOI: 10.5005/jp-journals-10018-1211

License: CC BY 3.0

Published Online: 01-12-2017

Copyright Statement:  Copyright © 2017; The Author(s).


Abstract

How to cite this article:

Gupta T, Rathi S, Dhiman RK. Managing Encephalopathy in the Outpatient Setting. Euroasian J Hepato-Gastroenterol 2017;7(1):48-54.

HTML PDF Share
  1. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the study of liver diseases and the European Association for the study of the liver. Hepatology 2014 Aug;60(2):715-735.
  2. The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat Rev Gastroenterol Hepatol 2013 Sep;10(9):522-528.
  3. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology 1998 Nov;28(5):1215-1225.
  4. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001 May;16(5):531-535.
  5. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol 2007 Jul;47(1):67-73.
  6. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009 Sep;137(3):885-891.
  7. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004 Mar;39(3):739-745.
  8. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol 2014 Nov;109(11):1757-1763.
  9. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001 May;34(5):768-773.
  10. Figure connection test: a universal test for assessment of mental state. J Gastroenterol Hepatol 1995 Jan-Feb;10(1):14-23.
  11. Diagnosis of minimal hepatic encephalopathy. J Clin Exp Hepatol 2015 Mar;5(Suppl 1):S54-S59.
  12. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002 Feb;35(2):357-366.
  13. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007 Apr;45(4):879-885.
  14. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology 2013 Sep;58(3):1122-1132.
  15. Diagnosis of minimal hepatic encephalopathy using StroopEncephalApp: a multicenter US-based, norm-based study. Am J Gastroenterol 2016 Jan;111(1):78-86.
  16. Prospective comparative study of inhibitory control test and psychometric hepatic encephalopathy score for diagnosis and prognosis of minimal hepatic encephalopathy in cirrhotic patients in the Indian subcontinent. J Dig Dis 2015 Jul;16(7):400-407.
  17. International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). Review article: the design of clinical trials in hepatic encephalopathy – an international society for hepatic encephalopathy and nitrogen metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011 Apr;33(7):739-747.
  18. Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy. World J Gastroenterol 2016 May;22(17):4397-4402.
  19. Is cognitive impairment in cirrhotic patients due to increased peroxynitrite and oxidative stress? Antioxid Redox Signal 2015 Apr;22(10):871-877.
  20. Nonabsorbable disaccharides for hepatic encephalopathy: a systematic review and meta-analysis. Hepatology 2016 Sep;64(3):908-922.
  21. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010 Mar;362(12):1071-1081.
  22. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014 Dec;147(6):1327-1337.
  23. The effects of probiotics and symbiotics on risk factors for hepatic encephalopathy: a systematic review. J Clin Gastroenterol 2017;51(4):312-323.
  24. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998 May;28(5):856-864.
  25. The nutritional management of hepatic encephalopathy in patients with cirrhosis: international society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology 2013 Jul;58(1):325-336.
  26. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013 Jun;57(6):2448-2457.
  27. Lactulose improves cognitive functions and health-related quality of life in cirrhotic patients with minimal hepatic encephalopathy. Hepatology 2007 Mar;45(3):549-559.
  28. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011 Feb;106(2):307-316.
  29. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997 Jun;25(6):1351-1360.
  30. Comparative effectiveness of different pharmacological interventions for the treatment of minimal hepatic encephalopathy: a systematic review with network meta-analysis. Hepatology 2016 Jul;64(Suppl 1):S54.
  31. Managing encephalopathy in the outpatient setting. Clin Liver Dis 2016 Dec;8(6):150-155.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.